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EDITORIAL
Intrathecal Opioids for Chronic Pain:
A Call for Evidence
The first implanted fixed rate pumps were used in humans
in the mid 1980s [1]. In 1991 Medtronic® released the first
programmable pump for human use [2]. The majority of
the research and reports concern programmable pumps,
and the best and most current systematic review of the
literature only identified manuscripts on these devices,
and only considered chronic non-malignant pain (AKA
chronic non cancer pain- CNCP) [1]. Older reviews are
available [3–5]. No review, nor our literature search, iden-
tified a Randomized Controlled Trial (RCT) of implantable
pumps using opioids in CNCP; yet despite such lack of
evidence, the devices are commonly used for patients
with CNCP. In contrast, there is an FDA drug registry of
RCTs available for implantable pumps using ziconotide in
CNCP [6]; IntraThecal (IT) baclofen has been assessed for
spasticity (but no RCT: see Taricco et al [7].) and in the
management of the dystonia of Complex Regional Pain
Syndrome [8]. There is a good RCT of implantable pumps
using opioids in cancer pain showing modest efficacy but
substantial risk [9].
Case reports, open label series and anecdotes abound for
opioid pumps in CNCP, but no RCT. The most remarkable
feature of this embarrassing situation is that the function-
ality of the device and the physiological/pharmacological
interface actually inherently lend themselves to the ran-
domized controlled trial. Randomization is straightforward.
The device can easily be programmed to deliver or not
deliver drug, leading to an excellent patient/subject blind.
The side effects of delivery could theoretically unblind the
subject, but most of these are subtle and cumulative (and
that feature can and should be definitively tested, for
instance with active controls). Additionally, all operators
except the programmer can be blinded, making a “one
and a half blind” simple to implement. Why an RCT in a
standard chronic pain model with standard methodology
has not be performed after 25 years of use is a (partial)
mystery. The lack of funding pretext is not rational, as the
high profit margin from these devices should be persua-
sive to industry support for executing definitive efficacy
experiments. So what then, is the hold up?
A risk:benefit analysis is difficult to assess in the absence
of evidence of efficacy, but reviews of complications raise
concerns about the procedure. In the Turner et al. sys-
tematic review, the weighted mean suggests that 41%
had urinary retention, 37% of who required catheterization
“for several days”; nausea/vomiting, 33%; pruritus, 26%;
“catheter-related complications” (migration, occlusion, or
mechanical failure), 18%; pump “malposition”, 17%;
wound infection, 12%; meningitis 3%; the Perez et al.
review of baclofen IT pumps mentions Post Lumbar punc-
ture headache [8], but Turner concludes this is “not . . .
common . . .” [1]. 27% of patients required “equipment
revisions” (Turner). Many other complications are reported
rarely (see Table 5 in Turner et al.) [1]. Serious side effects
are reported rarely. There have been 2 overdose deaths
reported due to operator error. Other serious documented
side effects include intrathecal granulomas with neurologic
dysfunction, traumatic syrinx, transverse myelitis, and
withdrawal symptoms with pump failure or removal [1].
The cost of IT pumps is very substantial. The original
implantation can run $30,000 to $40,000, with periodic
refills (as often as monthly) running $500/visit and up.
Again, without clear efficacy data it is difficult to assess the
cost:benefit ratio.
The rationale for “resorting” to opioid pumps in chronic
pain often relies on the argument that pain is “intractable”
or “refractory”; however, the available literature indicates
that this usually means failure of a modest array of
sequential drug trials to provide adequate reported relief,
and not optimized efficacious interdisciplinary care [10].
In the spirit of “responsible use and development” we
must conclude that there is a critical and immediate need
for good science in the use of IT pumps, specifically
concerning the common use of opioids in implantable
pumps for the management of refractory chronic pain
conditions. Until evidence is available, this technology
must be considered experimental, and as such the ethics
of continuing to use (and bill for) this intervention (after 25
years of empirical use) is highly questionable. The des-
peration of patients in chronic pain, and the desire for
simple, immediate gratification may justify early use of a
technology for compassionate reasons, but after a quarter
century simple empiricism is no longer tenable.
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